SCHEMBL6840242

SCHEMBL6840242

Cc1cc2c(Cl)c(C(=O)Cl)sc2cc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 3/20 0.45
▸ BCKDK O14874 2/20 0.45
▸ BCL2L1 Q07817 1/20 0.45
▸ RXFP1 Q9HBX9 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.40
▸ RAB9A P51151 7/20 0.40
▸ NPC1 O15118 6/20 0.40
▸ MAPT P10636 4/20 0.40
▸ LMNA P02545 3/20 0.40
▸ GAA P10253 2/20 0.40
▸ PPARG P37231 2/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ TSHR P16473 2/20 0.39
▸ PRNP P04156 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ NCOA2 Q15596 1/20 0.39
▸ PTGS1 P23219 1/20 0.37
▸ MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3063440 0.88 BCKDK (0.49) MCL1BCKDKBCL2L1RXFP1KDM4E
SCHEMBL6840188 0.87 MCL1 (0.60) MCL1BCKDKBCL2L1RXFP1KDM4E
SCHEMBL1254412 0.82 MCL1 (0.51) MCL1BCKDKBCL2L1RXFP1KDM4E
SCHEMBL694056 0.81 BCKDK (0.43) MCL1BCKDKBCL2L1RXFP1KDM4E
SCHEMBL6840187 0.81 MCL1 (0.60) MCL1BCKDKBCL2L1RXFP1KDM4E
SCHEMBL6025520 0.80 STING1 (0.52) MCL1BCKDKBCL2L1RXFP1KDM4E
SCHEMBL5214901 0.78 STING1 (0.53) MCL1BCKDKBCL2L1RXFP1KDM4E
SCHEMBL6840237 0.77 COMT (0.45) MCL1BCKDKBCL2L1RXFP1KDM4E
SCHEMBL6026684 0.77 STING1 (0.40) MCL1BCKDKBCL2L1RXFP1KDM4E
SCHEMBL1255148 0.75 BCKDK (0.58) MCL1BCKDKBCL2L1RXFP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962607-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-02-24 — — US disclosed
US-8741887-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2014-06-03 — — US disclosed
US-8722658-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-05-13 — — US disclosed
US-8623858-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-01-07 — — US disclosed
US-20130244997-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (US) 2013-09-19 — — US disclosed
US-20130237517-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (US) 2013-09-12 — — US disclosed
US-20130217669-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (US) 2013-08-22 — — US disclosed
US-20130137674-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA, NV (US) 2013-05-30 — — US disclosed
US-20130123233-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (US) 2013-05-16 — — US disclosed
US-20130123232-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (US) 2013-05-16 — — US disclosed
US-20130102585-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (US) 2013-04-25 — — US disclosed
US-8399454-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA, NV (BE) 2013-03-19 — — US disclosed
US-8362000-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2013-01-29 — — US disclosed
US-20110015170-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-01-20 — — US disclosed
US-20110015171-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015171-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA MCL1 2183/4885BCKDK 742/4885BCL2L1 3024/4885
US-20130244997-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA MCL1 2183/4885BCKDK 742/4885BCL2L1 3024/4885
US-20130217669-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA MCL1 2183/4885BCKDK 742/4885BCL2L1 3024/4885
US-20110015170-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA MCL1 2183/4885BCKDK 742/4885BCL2L1 3024/4885
US-20130123233-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA MCL1 2183/4885BCKDK 742/4885BCL2L1 3024/4885
US-20130237517-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA MCL1 2183/4885BCKDK 742/4885BCL2L1 3024/4885
US-20130137674-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA MCL1 2183/4885BCKDK 742/4885BCL2L1 3024/4885
US-20130102585-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA MCL1 2183/4885BCKDK 742/4885BCL2L1 3024/4885
US-20130123232-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA MCL1 2183/4885BCKDK 742/4885BCL2L1 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback